Evaluate sepsis AI tools by FDA status, intended use, data inputs, clinician suspicion, alert routing, local validation, privacy, and governance.
Representative source image: official Bayesian Health product page.
Quick answer: Sepsis AI tools should be evaluated as high-risk clinical decision support or medical-device software. Confirm whether the product is cleared for continuous monitoring or for suspected-sepsis risk assessment, validate performance locally, define who acts on alerts, and monitor missed cases, false positives, time to treatment, equity, and alert fatigue after launch.
Who this guide is for
Sepsis committees, emergency departments, hospitalists, infectious disease leaders, nursing, quality, clinical informatics, CMIOs, and AI governance teams evaluating sepsis detection or risk workflows.
What makes this workflow different
Sepsis AI spans continuous monitoring, suspected-sepsis diagnostics, EHR alerts, biomarkers, and care bundles, so intended use changes the safety, FDA, and workflow checks.
What to verify before using it
Confirm the exact FDA, De Novo, 510(k), CE, UKCA, or local regulatory status and whether the intended use requires clinician suspicion, blood-culture order, biomarkers, or continuous monitoring.
Map every data input, including EHR signals, vital signs, labs, demographics, biomarkers, device data, and sepsis-bundle workflow events.
Define alert recipients, escalation thresholds, override rules, downtime plans, documentation expectations, and who owns response when AI conflicts with bedside assessment.
Run local validation for sensitivity, specificity, positive predictive value, lead time, missed sepsis, false positives, subgroup performance, and alert burden before scaling.
Write the workflow in one sentence, decide who reviews the AI output, and test with a small controlled pilot before expanding.
Recommended posture
Use AI as supervised workflow support. Verify sources, privacy, human review, and regulatory fit before relying on outputs.
Source-backed products for this workflow
These profiles are not rankings. They are starting points for checking vendor claims, privacy terms, FDA or regulatory posture, evidence, and workflow fit.
Cytovale describes IntelliSep as an FDA-cleared rapid in vitro diagnostic test for sepsis that uses microfluidics, deformability cytometry, high-throughput image analysis, and machine learning to translate white-blood-cell features into an IntelliSep Index band; FDA K220991 describes the cleared adult ED suspected-infection intended use and states the test should be used with other clinical information and judgment.
Best for
Hospitals that want a rapid, lab-run host-response signal to support supervised ED sepsis triage, protocol decisions, and stewardship review.
First check
FDA 510(k) K220991 intended use, any subsequent IntelliSep clearances, adult ED suspected-infection population, prescription-use status, sample requirements, and three-day sepsis-with-organ-dysfunction window.
Bayesian Health describes a real-time clinical intelligence platform that reads EHR signals, adapts to patient baselines, surfaces risk, guides clinicians inside workflows, and reports published and real-world outcome claims; FDA records list K250680 for the Bayesian Health Sepsis Flagging Device as a Class II software device to aid sepsis prediction or diagnosis.
Best for
Hospitals evaluating governed clinical AI for sepsis, deterioration, or other inpatient risk workflows where alerts need context, clinician trust, and performance monitoring.
First check
Whether the deployment uses the FDA-cleared Bayesian Health Sepsis Flagging Device K250680, another Bayesian module, or a broader clinical pathway workflow.
Prenosis describes Sepsis ImmunoScore as an FDA De Novo-authorized AI sepsis diagnostic and predictive tool that combines up to 22 patient parameters, biomarkers, vital signs, demographics, and EHR data; FDA records list DEN230036, and Roche navify materials describe cloud-based algorithm-suite deployment and intended-use boundaries.
Best for
Hospitals evaluating transparent sepsis risk stratification that combines clinical data and biomarkers with EMR-integrated review for suspected sepsis workflows.
First check
FDA De Novo DEN230036 intended use, patient eligibility, blood-culture-order requirement, 24-hour risk window, and prescription-use limits.
Mednition describes KATE as a clinical AI platform for emergency department triage, sepsis recognition, and clinical analytics that reads structured and unstructured EHR data; company materials describe KATE Sepsis as having FDA Breakthrough Device Designation, while FDA guidance explains that designation is not the same as marketing authorization.
Best for
Hospitals evaluating AI as a triage safety net for emergency nurses where alerts can be governed through ED, sepsis, nursing, quality, and informatics workflows.
First check
Which module is in scope: KATE Triage, KATE Sepsis, Clinical Data Engine, reporting dashboards, or retrospective cohort analytics.
Sources
6 official sources
Official source trail for this workflow
Open these vendor, documentation, privacy, or regulatory sources before relying on product claims, especially for FDA status, PHI handling, deployment model, and intended use.
Find the best AI for medical workflows by matching the tool to documentation, questions, diagnosis support, research, coding, billing, imaging, or practice operations.
Understand AI for medical diagnosis, including validation evidence, FDA status, clinical supervision, and why patient-specific diagnosis should not rely on general chatbots.
